Board of Directors
Julian Baines, MBE (Non-Executive Chairman)
Julian is the Company’s Non-executive Chairman and Julian previously held the position of Non-executive Chairman of Renalytix AI plc between 2018 and 2020.
Julian is the Chief Executive Officer of EKF Diagnostics Holdings plc (EKF), having assumed the role in December 2009. During his tenure at EKF, he has successfully completed multiple fundraisings and the acquisition and subsequent integration of eight businesses in seven countries, building revenue from zero to over £40 million. Prior to joining EKF, Julian was group Chief Executive Officer of BBI Holdings plc, where he undertook a management buyout in 2000, its admission to AIM in 2004 and was responsible for selling the business to Alere, Inc. (now part of Abbott Laboratories) in 2008 for c. £85 million. In 2016, Julian was awarded an MBE (Member of the British Empire) for services to the life sciences industry.
Monique Fayad (Chief Executive Officer)
Monique is the former CEO and Co-Founder of ICDLogic, a provider of digital health information tools to clinicians and healthcare administrators which was acquired by iCoreConnect in 2017. She is also a former Senior Vice President, Strategy and Digital Development at Elsevier Health Sciences and HCPro and helped to build and launch five digital health products including CodeGenius, HCPro Comply, OncologySTAT, and Cardiosource. Monique provided consultancy services to MSIP in relation to the Company before being recruited as CEO. Monique received a B.S. in business studies from Chestnut Hill College and an MBA from the Leonard N. Stern School of Business at New York University.
Dr. Marla Dubinsky (Non-Executive Director, Co-Founder)
Marla Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in IBD at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before joining ISMMS as the Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children’s Hospital. She is also the Co-Director of the Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally in the US and has published in 160 peer reviewed journals including Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.
Dr. Erik Lium, PhD (Non-Executive Director)
Erik will represent ISMMS on the Board as part of the ongoing relationship between the Company and ISMMS.
Erik is the President of Mount Sinai Innovation Partners and Executive Vice President and Chief Commercial Innovation Officer of Mount Sinai Health System, where he is responsible for advancing ISMMS’ research, instruction, and public service missions through strategic research partnerships with industry, the management, transfer and commercialisation of technologies, and fostering the development of start-ups and joint ventures to advance promising early-stage technologies and enhance ISMMS’ research and clinical enterprises. He is a Non-executive Director of Renalytix AI plc and is chair of their audit and remuneration committees and he is also a Non-executive Director of Verici Dx plc and is chair of their remuneration committee.
Prior to joining ISMMS, Erik served as the Assistant Vice Chancellor of Innovation, Technology and Alliances at the University of California, San Francisco (UCSF), and the UCSF Principal Investigator for the Bay area National Science Foundation I-Corps node. Erik also previously served as a member of the Investment Review Committee for the Accelerate NY Seed Fund. He held previous positions at UCSF, including Assistant Vice Chancellor of Research and Director of Industry Contracts. Erik served as President of LabVelocity Inc., an Information Services Company focused on accelerating research and development in the life sciences, prior to its acquisition in 2004. He pursued post-doctoral research at UCSF in the laboratory of J. Michael Bishop, MD, and earned a PhD with honours from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein. Erik holds a BS in Biology from Gonzaga University
Mike Salter (Non-Executive Director)
Mike Salter is the President of EKF Diagnostics’ American business where he is responsible for all USA facilities including sales, operations and Regulatory Affairs, and also has a particular focus on EKF Life Sciences in Elkhart, Indiana. Previously, Mike worked at GE Healthcare where he was General Manager for the Custom Molecular Reagent Business within GE Life Sciences. He spent a total of 33 years with GE and Amersham in a variety of positions in the UK, Canada and USA.
Christopher Mills (Non-Executive Director)
Christopher Mills founded Harwood Capital Management in 2011, a successor from its former parent company J.O. Hambro Capital Management (“Harwood”), which he co-founded in 1993. He is Chief Executive Officer and investment manager of North Atlantic Smaller Companies Investment Trust plc and Chairman and Chief Executive Officer of Harwood Capital Management Ltd. Prior to that, Mr. Mills was a Director of Invesco MIM, where he was head of North American Investments and Venture Capital, and of Samuel Montagu International. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, RenalytixAI plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University.
Niyum Gandhi (Independent Non-Executive Director)
Niyum Gandhi has vast experience in integrated, value-based health care and is Chief Financial Officer and Treasurer at Mass General Brigham (Boston, MA) in which his responsibilities include financial oversight of $14 billion in operations with assets of approximately $21 billion, and management within the areas of Corporate Finance, Managed Care, Real Estate and Treasury.
Prior to his position at Mass General Brigham, Niyum served as the Executive Vice President, Chief Financial Officer and Chief Population Health Officer at Mount Sinai Health System. In this role, in addition to overseeing the financial operations of the organisation’s eight hospitals and ISMMS, he built ISMMS’ clinically integrated network, direct-to-employer business unit and consumer digital function in his role leading population health and consumer solutions. Prior to his position at ISMMS, Niyum served as a partner in the Health and Life Sciences consulting practice of Oliver Wyman in Chicago, where he focused on value-based health care strategy and transformation for physician groups, hospitals, and health plans. At Oliver Wyman, Niyum also worked with a variety of Accountable Care Organizations (ACOs) and other population health management companies, helping them design and implement value-based clinical models, develop value-based contracts and integrated product distribution strategies, align physician incentives toward value, and establish the appropriate infrastructure to support population health management.
Niyum holds an AB in economics and finance from Harvard University. He has authored several articles on ACOs, payer/provider partnerships, and physician engagement and serves as a regular conference speaker on a variety of issues related to population health and value-based care.
Dr. Daniel Mahony, (Independent Non-Executive Director, Senior Independent Director)
Dan launched the healthcare business at Polar Capital in 2007 and the team now has $4 billion of assets under management. Dan serves as Co-Head of the team and his current focus is on how technology will be a catalyst for the disintermediation and disaggregation of healthcare. Dan was formerly head of European healthcare research at Morgan Stanley, an analyst at ING Barings Furman Selz in New York and a research scientist including at Schering Plough, CA. He has over 25 years of experience within global healthcare covering biotechnology, medical technology and healthcare services.
Dan holds non-executive directorships at the Wellcome Sanger Institute (a world leading genomics research centre that operates under the name of Genome Research Limited), Celmatix (a privately held, preclinical-stage women’s health biotech in NY focused on ovarian biology), Keepabl (a UK based, privately owned provider of SaaS solutions for GDPR compliance), Apian (a privately held healthcare drone startup, founded by NHS doctors in training)], and the Bio-industry Association (BIA), the industry trade association for UK life sciences, where he also chairs the audit committee, and also acts as a mentor for the NHS Clinical Entrepreneur Training Programme, which aims to support junior doctors and health professionals in developing their entrepreneurial aspirations during clinical training. Dan is also the founder and Director of DKM (Restharrow) Consulting, a privately owned consulting company.